X4 Pharmaceuticals Inc
NASDAQ:XFOR

Watchlist Manager
X4 Pharmaceuticals Inc Logo
X4 Pharmaceuticals Inc
NASDAQ:XFOR
Watchlist
Price: 3.88 USD -0.26% Market Closed
Market Cap: 339.3m USD

Net Margin
X4 Pharmaceuticals Inc

-279.9%
Current
-29%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-279.9%
=
Net Income
-95.1m
/
Revenue
34m

Net Margin Across Competitors

No Stocks Found

X4 Pharmaceuticals Inc
Glance View

Market Cap
339.3m USD
Industry
Biotechnology

X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company is headquartered in Boston, Massachusetts and currently employs 83 full-time employees. The company went IPO on 2017-11-16. The firm is focused on the research, development and commercialization of therapeutics for the treatment of rare diseases with an initial focus on the treatment of people with immune system dysfunction. Its lead product candidate, mavorixafor, is a small molecule inhibitor of the chemokine receptor CXCR4 and is being developed as a once-daily oral therapy. Its mavorixafor demonstrated ability to antagonize CXCR4 and improve the healthy maturation and trafficking of white blood cells (WBCs), which provides therapeutic benefit across a variety of diseases, including primary immunodeficiencies (PIDs) and certain types of cancer. Its mavorixafor is in a global Phase III clinical trial for the treatment of warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome, a rare, inherited PID caused by genetic mutations in the CXCR4 receptor gene. Its product candidates include X4P-001, X4P-002 and X4P-003.

XFOR Intrinsic Value
2.81 USD
Overvaluation 27%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-279.9%
=
Net Income
-95.1m
/
Revenue
34m
What is the Net Margin of X4 Pharmaceuticals Inc?

Based on X4 Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of -279.9%.

Back to Top